Blood volume

Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Retrieved on: 
torsdag, januari 6, 2022
DXR, BVA, Forward-looking statement, Patient, NYSE, Conference, Private Securities Litigation Reform Act, CEO, SEC, FDA, Patent, Blood volume, Heart failure, GLOBE, Risk, Critical care

Oak Ridge, TN, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh will present a corporate overview at the H.C. Wainwright BioConnect 2022 Virtual Conference, which is taking place on January 10 13, 2022.

Key Points: 
  • Oak Ridge, TN, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh will present a corporate overview at the H.C. Wainwright BioConnect 2022 Virtual Conference, which is taking place on January 10 13, 2022.
  • Mr. Feldshuh will provide company updates and key highlights, including a new patent award and progress with BVA-100 next generation development.
  • Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation.
  • Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

DAXOR AWARDED NEW PATENT FOR BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES

Retrieved on: 
tisdag, januari 4, 2022
National, Private Securities Litigation Reform Act, Heart failure, Risk, BVA, DXR, FDA, AI, Critical care, GLOBE, NYSE MKT, Physician, SEC, CEO, Trauma, NYSE, Patient, Patent, 1836 U.S. Patent Office fire, Technology, Blood volume, Forward-looking statement, Pharmaceutical industry

Oak Ridge, TN, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced that the United States Patent and Trademark Office has issued the company a new patent (U.S. Patent No. 11,204,356 B2) that protects a proprietary clinical guidance system for volume management utilizing unique volume metrics combined with treatment pathways.

Key Points: 
  • 11,204,356 B2) that protects a proprietary clinical guidance system for volume management utilizing unique volume metrics combined with treatment pathways.
  • "We are very excited to receive this patent, which covers key innovations in the use of blood volume analysis to optimally guide fluid treatment, said Jonathan Feldschuh, Chief Scientific Officer of Daxor.
  • Modern medicine demands smarter systems with AI and advanced guidance to optimize care; this patent broadly protects Daxors leading technology for the use of smart blood volume systems to achieve optimal outcomes.
  • Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation.

Axo Nutrition Introduces Latest Pre-Workout and Recovery Gummy

Retrieved on: 
tisdag, december 28, 2021
Muscle fatigue, Fats, BCAA, Amazon, Fatigue, Glutamine, SAN, Athlete, Protein, Blood volume, Exercise, Nutrient, Pre-workout, Rest, Chromium, Industry, Chromium(III) picolinate, Muscle contraction, Time, Burn, Nutrition, Goal, Dietary supplement, Milk, Caffeine, Sodium, Β-Alanine

SAN DIEGO, Dec. 28, 2021 /PRNewswire-PRWeb/ --AXO Nutrition, a Southern California-based performance nutrition company, today announced its newly developed Pre-Workout and Recovery Gummies.

Key Points: 
  • SAN DIEGO, Dec. 28, 2021 /PRNewswire-PRWeb/ --AXO Nutrition, a Southern California-based performance nutrition company, today announced its newly developed Pre-Workout and Recovery Gummies.
  • The core goal of the Recovery Gummy is to get people back to normal faster after a physically taxing workout or event.
  • AXO Nutrition is trying to disrupt a $35B industry one gummy at a time.
  • At AXO Nutrition we want everyone to have that little extra something to power their day and help them accomplish their goals.

Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Optimal Heart Failure Management at Key Scientific Society Meeting

Retrieved on: 
tisdag, november 16, 2021
Health, Safety, Adoption, Private Securities Litigation Reform Act, AHA, Heart failure, New Studies in Medieval History, MD, Critical care, American Heart Association, CEO, Blood volume, DXR, Blood, Technology, LVAD, Forward-looking statement, PV, Anemia, Patient, Polycythemia, GLOBE, SEC, NYSE, Diagnosis, Hematocrit, Physician, BVA, Risk, FDA, TBV, Medical device, Pharmaceutical industry, Medical imaging

Oak Ridge, TN, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 blood test in identifying heart failure patient-specific phenotypes and detecting true anemia. These data from two separate studies were presented at the American Heart Association (AHA) Scientific Sessions virtual meeting from November 13-15, 2021.

Key Points: 
  • These data from two separate studies were presented at the American Heart Association (AHA) Scientific Sessions virtual meeting from November 13-15, 2021.
  • In heart failure, physicians seek to optimize a patients blood volume which has wide variations in total blood volume (TBV), plasma volume (PV) and red blood cell volume (RBCV).
  • This study shows that measuring with blood volume analysis (BVA) distinct phenotypes have emerged, which provides clinicians with actionable information to achieve optimal fluid management.
  • Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation.

New Research Demonstrates Clinical Utility of Daxor Corporation Blood Volume (BVA-100®) Diagnostic in Neurocritical Care

Retrieved on: 
tisdag, november 9, 2021
Mortality, Lists of diseases, ICU, NYSE MKT, Private Securities Litigation Reform Act, RCT, Septic shock, Neurocritical Care Society, Critical care, Nsah Mala, CEO, Blood volume, DXR, Prior, Research, Forward-looking statement, Surgery, NCS, GLOBE, Heart failure, Shock, SEC, NYSE, Physician, Patient, BVA, DCI, FDA, Risk, Acute respiratory distress syndrome, Pharmaceutical industry, Medical imaging

NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the clinical utility of the BVA-100 blood test in patients with non-traumatic subarachnoid hemorrhage (nSAH) presented at the virtual NeuroCritical Care Society (NCS) 19th Annual Meeting.

Key Points: 
  • The study titled, The Influence of Blood Volume Analysis on the Clinical Management of Non-Traumatic Subarachnoid Hemorrhage, surveyed whether intravascular volume assessments would influence clinical decision making in nSAH.
  • Non-traumatic subarachnoid hemorrhage can cause complicated, irreversible neurological injury and achieving optimal intravascular volume plays an important role in improving patient outcomes, said Michael Feldschuh, CEO and President of Daxor Corporation.
  • Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations).
  • We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms.

Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status

Retrieved on: 
lördag, november 6, 2021
Health, Other Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, People, LLY, Mortality, Population, Safety, Society, University, Corporation, SGLT2, Boehringer Ingelheim, Â, Lilly, Congestion, Therapy, Heart failure, Health, Heart, Trial, European Union, Blood volume, Disease, New product development, Blood, Risk, Union, Alliance, Multimedia, Research, Chronic kidney disease, Fatigue, University of Lorraine, Cardiovascular disease, Kidney disease, Gaps, Chronic, EMPOWER, Eli Lilly and Company, Cardiology, Hospital, NYSE, Kidney, Death, Physician, Diabetes, LVEF, Patient, EGFR, Pharmaceutical industry, Medical imaging, the EMPEROR heart failure studies, the EMPOWER program, heart failure, cardio-renal-metabolic conditions, empagliflozin, THE EMPEROR HEART FAILURE STUDIES, THE EMPOWER PROGRAM, HEART FAILURE, CARDIO-RENAL-METABOLIC CONDITIONS, EMPAGLIFLOZIN

The consistent benefits shown for the reduction of serious heart failure events and the slowing of kidney function decline regardless of chronic kidney disease status are welcome results for both patients and physicians.

Key Points: 
  • The consistent benefits shown for the reduction of serious heart failure events and the slowing of kidney function decline regardless of chronic kidney disease status are welcome results for both patients and physicians.
  • The findings underscore the potential value of empagliflozin across a wide range of kidney function in this heart failure population that includes people with preserved ejection fraction.
  • It is very encouraging to see the evidence from EMPEROR-Preserved, which shows cardiovascular and kidney benefits in these patients with heart failure, including those with HFpEF, and concomitant chronic kidney disease.
  • People with left-sided heart failure have either a reduced or a preserved ejection fraction.

Daxor Corporation Receives $200K Matching Fund Award from Launch Tennessee

Retrieved on: 
fredag, oktober 1, 2021
Heart failure, Partnership, SBIR, Agtech, Private Securities Litigation Reform Act, FDA, Patient, SEC, Blood volume, Entrepreneurship, BVA, Unemployment, Critical care, Life, Private sector, Small business, Risk, High-functioning autism, Technology, Forward-looking statement, Economic development, STTR, NYSE, Government, U.S. Department of Defense Strategy for Operating in Cyberspace, DXR, GLOBE, Department, Renewable energy, Pharmaceutical industry

Oak Ridge, TN, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announced Launch Tennessee (LaunchTN) has awarded Daxor Corporation a SBIR/STTR matching fund grant for Daxor’s Phase II award from the Department of Defense in the amount of $200K for the development of its next-generation point-of-care blood volume analyzer.

Key Points: 
  • The SBIR/STTR Matching Fund Grant Will Advance the Companys Innovation and Commercialization Efforts, and Job Creation
    Oak Ridge, TN, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announced Launch Tennessee (LaunchTN) has awarded Daxor Corporation a SBIR/STTR matching fund grant for Daxors Phase II award from the Department of Defense in the amount of $200K for the development of its next-generation point-of-care blood volume analyzer.
  • We are proud of our affiliation with the great state of Tennessee and are grateful to participate in this opportunity.
  • Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation.
  • Launch Tennessee (LaunchTN) is a public-private partnership with a vision to make Tennessee the most startup-friendly state in the nation.

US FDA approved IND submitted by Pharmazz, Inc. to initiate a phase III clinical trial of centhaquine in patients with hypovolemic shock

Retrieved on: 
onsdag, september 29, 2021
Blood, Vomiting, Hypovolemic shock, Mortality, Cardiac output, Trauma, Resuscitation, Gastrointestinal bleeding, Standard of care, Patient, Time-invariant system, Therapy, Advances in Therapy, Private Securities Litigation Reform Act, III, FDA, Blood volume, Phase, Acquisition, Company, Critical care, Meta-analysis, Internal bleeding, Risk, Hypovolemia, Bleeding, IND, Survival, Manuscript, Randomness, US, MODS, Diarrhea, Pharmaceutical industry

The Phase III clinical study will be a multi-centric, double-blind, placebo-controlled to be conducted on 430 patients randomly assigned equally to both arms with 28-day mortality as the primary endpoint.

Key Points: 
  • The Phase III clinical study will be a multi-centric, double-blind, placebo-controlled to be conducted on 430 patients randomly assigned equally to both arms with 28-day mortality as the primary endpoint.
  • Centhaquine, a resuscitative agent free of arterial constriction, IND for the Phase III trial approved by the US FDA
    Severe blood or fluid loss due to trauma, gastrointestinal bleeding, major surgery, postpartum hemorrhage, diarrhea, or vomiting can cause hypovolemic shock.
  • About 1.9 million people worldwide die because of hemorrhagic shock every year, most dying within the first 6 hours.
  • The peer-reviewed publication of the manuscript titled " A Multi-centric, Randomized, Controlled Phase III Study of Centhaquine (Lyfaquin) as a Resuscitative Agent in Hypovolemic Shock Patients."

Q30 Innovations Launches the First FDA-Cleared Sports Equipment To Help Protect Athletes' Brains During Head Impacts

Retrieved on: 
onsdag, september 15, 2021
Q30, Movement, Science, Head Injuries, Engineering, FDA, University, Technology, Hockey, Research, University of Toronto, Sport, Neck, Blood volume, Cincinnati Children's Hospital Medical Center, Brain, Head, Safety, Hospital, Ageing, Athlete, NorthShore University HealthSystem, Multimedia, Skull, Boston Children's Hospital, Department, Parent, Football, Head injury, Association, Medical device, Sports equipment

The device addresses a primary health concern in contact sports by providing an extra layer of protection for athletes of any contact sport.

Key Points: 
  • The device addresses a primary health concern in contact sports by providing an extra layer of protection for athletes of any contact sport.
  • The Q-Collar is intended to be worn around the neck with existing protective sports equipment.
  • By creating a tighter fit for the brain inside the skull, the Q-Collar is safe and effective at helping to protect athletes' brains from effects associated with repetitive sub-concussive head impacts.
  • Based in Westport, Conn., Q30 Innovations' mission is to help protect the brain from the effects of head impacts on the sports field and the battlefield.

Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Heart Failure Patients at Key Scientific Society Meeting

Retrieved on: 
tisdag, september 14, 2021
Appropriation, U.S. Department of Defense Strategy for Operating in Cyberspace, CEO, BMI, FDA, University, Health, Forward-looking statement, Center, FAAP, U.S. Department of Veterans Affairs, Office of Inspector General, Adoption, BVA, ASM, University of Tennessee Health Science Center, Private Securities Litigation Reform Act, DXR, Defense, Blood volume, Risk, National Institutes of Health Clinical Center, Ultrafiltration, NIH, FAHA, Veterans' affairs, NYSE, Physician, Heart failure, MD, Volume overload, Heart Failure Society of America, Phenotype, Contract, Critical care, MPH, GLOBE, Anemia, Population, FHFS, Face, Diuresis, Veteran, SEC, FACC, National Institute, LVAD, Medical imaging, Medical device, Pharmaceutical industry

“The data we regularly collect on use of the BVA-100 test consistently demonstrates that it provides the most accurate and reliable methodology to both personalize and optimize treatment in heart failure patients,” added Mr. Feldschuh. “We are encouraged by the growing recognition of the significant value and clinical adoption of the BVA-100 test to improve both clinical and economic outcomes -- we look forward to providing updates on these outstanding results.”

Key Points: 
  • Volume-Guided Venous to Venous Ultrafiltration in Hospitalized Heart Failure Patients: This pilot study combined blood volume analysis and ultrafiltration to safely remove fluid with volume overload.
  • Study authors indicated that earlier utilization of the BVA-100 test may have prevented the acute renal injury from their previous diuresis.
  • This study also measures the benefit of the BVA-100 test for improving ambulatory heart failure patient care, a population that numbers more than 6 million in the U.S. alone.
  • Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation.